The aptamers market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Aptamers are short, single-stranded DNA or RNA oligonucleotides that can bind to a specific target molecule. They have wide range of applications in diagnostics, research, therapeutics and also offer advantages over antibodies. Some key uses of aptamers include disease detection, targeted drug delivery, tissue regeneration and molecular imaging.
Market Dynamics:
The aptamers market is primarily driven by growing applications of aptamers in diagnostic and therapeutic areas. Aptamers offer advantages over antibodies such as ease of production and modification, high stability and affinity to target molecules. Further, research in development of new aptamers for diverse set of targets and clinical evaluation of aptamers candidates to treat various diseases is expected to offer lucrative growth opportunities. However, high development costs and regulatory complexities associated with aptamer development may restrain the market growth.
SWOT Analysis
Strength:
- High specificity and selectivity for target molecules. Aptamers can specifically bind to target molecules like proteins with high affinity and specificity.
- Cost effective production and modification. Aptamers can be produced through an in vitro selection process called SELEX which is cost effective as compared to production of monoclonal antibodies.
- Stable in storage and transport. Aptamers show good stability at room temperature and withstand multiple freeze-thaw cycles making them easy to store and transport.
Weakness:
- Susceptibility to nucleases. Being made up of nucleic acids, aptamers are susceptible to nuclease degradation in body fluids.
- Short shelf life. Without chemical modification, unmodified aptamers have relatively short shelf life.
Opportunity:
- Wide target spectrum. Aptamers have potential to target a wide range of molecules like proteins, cell surfaces, toxins, pathogens, small molecules making them suitable for various therapeutic and diagnostic applications.
- Personalized medicine. Selected aptamers against specific biomarkers or antigens can enable development of personalized medicine approaches.
Threats:
- Limited intellectual property protection. Development of similar aptamer sequences against same target by different players can pose challenge.
- Stringent regulatory approval process. Like other novel drug entities, aptamers also need to undergo long and expensive regulatory approval process before commercialization.
Key Takeaways
The Global Aptamers Market Size is expected to witness high growth, exhibiting CAGR of 18% over the forecast period, due to increasing demand for novel targeted therapeutics and diagnostics.
Regional analysis:
North America is currently the dominant region in the aptamers market owing to favorable regulatory environment and strong presence of leading players. The Asia Pacific region is poised to exhibit fastest growth due to increasing governmental support for development of advanced therapeutics and expanding healthcare infrastructure in developing countries like China and India.
Key players:
Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. These players are focusing on developing novel aptamer therapeutics and expanding their commercial presence worldwide through strategic collaborations.
Get More Insights Here
https://www.trendingwebwire.com/aptamers-market-share-size-forecast-outlook-2023-2030/
